This study is looking at how safe a medicine called eplontersen is for people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a heart problem caused by a build-up of harmful proteins. The study will involve around 1,400 people who will get eplontersen once every four weeks for up to three years. They will also take vitamin A daily. The study has three parts: a screening period, a treatment period, and a follow-up period.
- This study lasts up to 3 years with medicine given every 4 weeks.
- Participants must take vitamin A every day.
- Only people who finished an earlier related study or have ATTR-CM can join.